While HER2-positive BC comprises only around 20% of newly diagnosed cases, a greater proportion of patients (≈40–50%) have BC categorized as HER2-low, i.e., IHC of 1+ or 2+ but FISH negative [13,14,15]. This evidence concerns the gene ERBB2 and breast cancer.